Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

09-272022

Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company,...
08-022022

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, t...
05-102022

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

BAT7104 was designedto inhibit the PD-1/PD-L1 and CD47/SIRP-α pathways. By an “imbalanced” designwith finely tuned bindi...

上一页 ···18 19 20 21 22 ··· 下一页